RYK and ovarian carcinoma: Although most of such data derive from in vitro models using cancer cell lines, in vivo experimental data supporting oncogenic roles for ROR2 have been reported in melanoma [132], renal cell carcinoma [133], ovarian cancer [134], and breast cancer [135], as well as for RYK in gastric [136] and ovarian cancer [137].